Chief Scientific Officer, Infectious Disease
Danaher
Cary, NC, United States
Ephraim Tsalik is the VP and Chief Scientific Officer for Infectious Disease at Danaher Diagnostics. Dr. Tsalik joined the Duke University faculty in 2011, rising to tenured Associate Professor, where his research focused on host response biomarkers for infectious disease, supported by DARPA, DTRA, VA, CDMRP/U.S. Army, and the NIH. He co-founded Predigen, a company developing host gene expression diagnostics for infectious and inflammatory diseases, which was acquired by Biomeme. In April 2022, Dr. Tsalik joined Danaher Diagnostics to help realize the future of infectious disease diagnostics. He remains clinically active at the Durham VA Health Care System and maintains an adjunct appointment with Duke University. Dr. Tsalik serves on the Antibacterial Resistance Leadership Group Diagnostics Subcommittee and Innovations Working Group, having previously served as the Associate Director of the Laboratory Center. Dr. Tsalik obtained his MD and PhD from Columbia University and completed clinical training in Internal Medicine and Infectious Diseases at Duke University while earning a Master of Health Science in Clinical Research.
Disclosure(s): Danaher: Employment (Ongoing), Stocks/Bonds (Public Company) (Ongoing), Systems and methods for artificial intelligence based infection classification using cell parameters or populations (Ongoing)
156 - Leveraging the Host Response for Infectious Disease Diagnosis and Pathogen Discovery
Friday, October 18, 2024
1:45 PM – 3:00 PM US PT
353 - Host biomarkers for infectious diseases diagnosis: What’s current and what’s coming
Friday, October 18, 2024
1:45 PM – 2:10 PM US PT